Lung Cancer Biomarkers and Screening
RATIONALE: Screening tests that use biomarkers may help doctors find tumor cells early and plan effective treatment for lung cancer. PURPOSE: This clinical trial is studying biomarkers in screening participants for lung cancer.
Checked against the public recordLast updated May 8, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- NYU Langone Health
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
DISEASE CHARACTERISTICS: * Screening Cohort * At high- or low-risk for lung cancer * Smoking history ≥ 20 pack years\* * With or without workplace exposure to asbestos * NOTE: \* Participants with \< 20 pack years of smoking are eligible if 50 years of age or older * Rule-Out Lung cancer group * Referred for evaluation of suspicious nodules with 1 of the following diagnoses: * Lung cancer * Nonmalignant nodules (control group) PATIENT CHARACTERISTICS: * Not pregnant * No prior malignancy except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY: * Not specified
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- NYU Cancer Institute at New York University Medical CenterNew York, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 8, 2026. Always confirm current availability with the study team.